Diagnostic and prognostic molecular markers in common adult gliomas.

about

Diagnostic and prognostic molecular markers in common adult gliomas.

Item

http://www.wikidata.org/entity/Q44387794

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Diagnostic and prognostic molecular markers in common adult gliomas.

@en

Diagnostic and prognostic molecular markers in common adult gliomas.

@nl

type

Item

label

Diagnostic and prognostic molecular markers in common adult gliomas.

@en

Diagnostic and prognostic molecular markers in common adult gliomas.

@nl

prefLabel

Diagnostic and prognostic molecular markers in common adult gliomas.

@en

Diagnostic and prognostic molecular markers in common adult gliomas.

@nl

P1476

Diagnostic and prognostic molecular markers in common adult gliomas.

@en

P2093

Andreana L Rivera

http://www.w3.org/2001/XMLSchema#string

Christopher E Pelloski

http://www.w3.org/2001/XMLSchema#string

P2860

The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways

An integrated genomic analysis of human glioblastoma multiforme

IDH1 and IDH2 mutations in gliomas

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

P304

637-649

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERM.10.44

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20629512

http://www.w3.org/2001/XMLSchema#string